GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies
China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...
Vitalgen BioPharma
CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01
In a swift succession of actions, China’s Center for Drug Evaluation (CDE) has added two...
Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor
Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China,...
Yiming and Vitalgen’s Gene Therapy VGR-R01 Receives CDE Approval for Bietti Crystalline Dystrophy
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...